Biocon Intrinsic Value
Biocon (BIOCON) median intrinsic value is ₹580.80 from 8 valuation models (range ₹109–₹906), vs current price ₹362.25 — +60.3% upside (Trading Below Calculated Value), margin of safety 37.6%. For current market price and key ratios, visit BIOCON stock live price.
BIOCON Valuation Methods Summary — DCF, Graham Number & P/E
Biocon intrinsic value across 8 models vs current price ₹362.25 — upside/downside and value range per method. Browse BIOCON balance sheet details for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹108.67 | ₹86.94 - ₹130.40 | -70.0% | EPS: ₹2.64, Sector P/E: 22x |
| Book Value Method | asset | ₹905.62 | ₹815.06 - ₹996.18 | +150.0% | Book Value/Share: ₹461.88, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹580.80 | ₹522.72 - ₹638.88 | +60.3% | Revenue/Share: ₹290.40, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹589.33 | ₹530.40 - ₹648.26 | +62.7% | EBITDA: ₹3536.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹905.62 | ₹724.50 - ₹1086.74 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹108.67 | ₹97.80 - ₹119.54 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹108.67 | ₹97.80 - ₹119.54 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹165.64 | ₹149.08 - ₹182.20 | -54.3% | EPS: ₹2.64, BVPS: ₹461.88 |
BIOCON Intrinsic Value vs Market Price — All Valuation Models
Biocon fair value range ₹109–₹906 vs current market price ₹362.25 across 8 valuation models. Compare with BIOCON fair price to assess whether the stock is under or overvalued.
BIOCON Intrinsic Value Analysis — Undervalued or Overvalued?
Biocon median intrinsic value ₹580.80, current price ₹362.25 — Trading Below Calculated Value by 60.3%, margin of safety 37.6%.
What is the intrinsic value of BIOCON?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Biocon (BIOCON) is ₹580.80 (median value). With the current market price of ₹362.25, this represents a +60.3% variance from our estimated fair value.
The valuation range spans from ₹108.67 to ₹905.62, indicating ₹108.67 - ₹905.62.
Is BIOCON undervalued or overvalued?
Based on our multi-method analysis, Biocon (BIOCON) appears to be trading below calculated value by approximately 60.3%.
BIOCON Financial Health — Key Ratios vs Industry Benchmarks
Biocon financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.97 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 1.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.30x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
BIOCON Cash Flow Quality — Operating & Free Cash Flow
Biocon operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹4,061 Cr | ₹3,960 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹2,954 Cr | ₹2,453 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹1,853 Cr | ₹-5,277 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹1,177 Cr | ₹346 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹1,160 Cr | ₹-666 Cr | Positive Operating Cash Flow | 6/10 |